NCT05656131

Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer

Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer，A Two-cohort, Open, Multicenter，Phase II Study

• Status: Suspended
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: wang shusen · Academic / Other
• Sex: Female
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This study is planned to include 80 patients with HRD positive HER2-negative advanced breast cancer to receive fluzoparib alone or fluzoparib combined with camrelizumab to observe and evaluate the efficacy and safety of fluzoparib combined with or without camrelizumab in the treatment of HRD positive HER2-negative advanced breast cancer.

Conditions

• Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer

Interventions

Type	Name	Description
DRUG	Fluzoparib	Arms A will be treated with fluzoparib alone
DRUG	Fluzoparib+Camrelizumab	Arms B will be treated with fluzoparib in combination with camrelizumab

Timeline

• Start date: 2022-11-23
• Primary completion: 2026-03-30
• Completion: 2027-12-31
• First posted: 2022-12-19
• Last updated: 2026-03-17

Locations

1 site across 1 country: China